MedTrace Logo

Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC

NCT02835924 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 299

Last updated 2020-03-10

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.

Conditions

Interventions

DRUG

Regorafenib

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    lead OTHER

Principal Investigators

  • Guillem Argiles · Hospital Universitary Vall d'Hebron

  • Josep Mª Tabernero, MD-PhD · Hospital Universitary Vall d'Hebron

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-09-30
Completion
2019-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02835924 on ClinicalTrials.gov